A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4) in Advanced Malignant Tumours


Lymphoma -> diffuse large b-cell lymphoma (DLBCL)


Diffuse large b-cell lymphoma (DLBCL) is the most common type of lymphoma. This form of cancer requires treatment when diagnosed, and commonly involves a combination of chemotherapy and immunotherapy medications.

This trial is for patients who have diffuse large b-cell lymphoma which has returned after treatment. Patients will receive BMS-986205 and nivolumab. BMS-986205 is a new drug taken by mouth, and works by blocking a protein called IDO1 which can help the immune system fight the cancer cells. Nivolumab is given through an intravenous drip and works by ‘revealing’ the cancer to the immune system to be killed.

The aim of the trial is to see whether the combination of medications is effective and well tolerated in treating diffuse large B-cell lymphoma.


Include, but not limited to, the following:

- Patients must be aged 18 or over
- A diagnosis of diffuse large B-cell lymphoma that has continued to grow (refractory) or returned (relapsed) after at least one line of treatment
- No other active cancers (other than some cancers cured with minor operations like skin cancer)
- No other major health problems

Contact person:

Zelda Herbst


Phone 08 6382 5100

Principal Investigator:

Professor Michael Millward

08 6382 5100


Bristol-Myers Squibb Australia



Protocol Number:


Trial Registration Number:



ANZ Clinical Trial Registry